nChroma Bio

Executive Summary

nChroma Bio is a privately held genetic medicines company founded in 2020, headquartered in San Francisco. The company is pioneering a modular platform that combines targeted lipid nanoparticles (LNPs) and engineered virus-like particles (eVLPs) to deliver tailored genetic cargoes for in vivo therapies. Its primary focus is on overcoming the limitations of current treatments for extrahepatic diseases, with a lead program aimed at achieving a functional cure for chronic hepatitis B virus (HBV). By enabling targeted delivery beyond the liver, nChroma's platform has the potential to unlock a wide range of therapeutic applications, including rare genetic disorders and oncology. The company leverages advanced AI and machine learning to optimize particle design and cargo selection, enhancing specificity and efficacy while minimizing off-target effects.

Upcoming Catalysts (preview)

• Q3 2026Series B Financing Round80% success
• Q4 2026Preclinical Proof-of-Concept Data for HBV Program70% success
• H1 2027Partnership with Major Pharma for Platform Access50% success